91É«ÇéƬ

Time

Activity

Director's welcome

Professor Michael Farrell

Director, National Drug and Alcohol Research Centre (NDARC), 91É«ÇéƬ Sydney

Ozempic and substance use disorders panel discussion: Could GLP-1 receptor agonists transform addiction medicine?

Ìý

Panellists:

• Professor Michael Farrell, Director, NDARC, 91É«ÇéƬ Sydney

• Dr Mary Harrod, Chief Executive, NUAA

• Professor Gavan McNally, Head of the Behavioural Neuroscience Research Group at the School of Psychology, 91É«ÇéƬ Sydney

• Professor Paul Haber AM, Executive Director Research for the Sydney Local Health District; Conjoint Professor at the University of Sydney

• Professor Sallie Pearson, Head the Medicines Intelligence Research Program at the School of Population Health, 91É«ÇéƬ Sydney

Three decades of Drug Trends: Emerging patterns and future directions

Associate Professor Amy Peacock

Deputy Director and Drug Trends Program Lead, NDARC, 91É«ÇéƬ Sydney

Spotlight on the National Centre for Clinical Research on Emerging Drugs (NCCRED)

• Stassi Kypri:ÌýNon-prescribed ketamine use in Australia: Results from a web-based survey

• Simon Caldwell:ÌýNavigating novel benzos: The practices & experiences of people sourcing benzodiazepines from unregulated markets

• Dr Krista Siefried:ÌýGHB & its precursors in Australia: Rising harms, shifting markets, & evolving risk behaviours

Illicit drug-related harms in Australia

• Dr Michala Kowalski and Dr Nic Taylor:ÌýIllicit Alcohol in Australia: Initial availability estimates & known harms

• Dr Rachel Sutherland:ÌýShifting nicotine landscapes: Illicit tobacco, vaping, & emerging products among people who use drugs

• Dr Natasa Gisev:ÌýSeasonal variations in drug-induced deaths in Australia, 2000-2021

Breakout session one: Maternal health and young people

Ìý

• Dr Alys Havard:ÌýThe effectiveness and safety of smoking cessation pharmacotherapies during pregnancy

• Dr Danielle Tran:ÌýEngagement and retention in opioid agonist treatment during pregnancy and postpartum

• Dr Bianca Varney:ÌýUse and safety of prescription opioid analgesics during pregnancy and postpartum

• Sarah Ticehurst:ÌýYouth co-design of longitudinal research: A mixed-methods evaluation of the IMPACT Youth Council

Breakout session two: Treatment and provision of care

Ìý

• Lucy Tran:ÌýThe impact of major depressive disorder on treatment outcomes for people with methamphetamine dependence

• Dr Brendan Clifford:ÌýA pilot study of Ketamine-Assisted Psychotherapy for Methamphetamine Use Disorder

• Kendal Chidwick:ÌýModels of service delivery for opioid use disorder medications: A systematic review and meta-analysis of randomised controlled trials and observational studies

• Khine Wut Yee Kyaw:ÌýPrevalence of health service utilisation prior to drug deaths: A systematic review and meta-analysis

• Dr Liam Acheson:ÌýStigma towards people who use drugs in frontline non-clinical healthcare workers

Breakout session three: Engaging communities

Ìý

• Lily Palmer:ÌýHarm reduction strategies among people who use illicit stimulants: Naloxone and drug checking in Australia

• Cilla Zhou and Jess Doumany:ÌýPartnership as method: Co-developing an evaluation framework for peer engagement in the OLAM trial

• Dr Simon Clay:Ìý‘Wherever they’re at is wherever they’re at, right?’: Substance use and informal cultures of care among members of the queer community

• Dr Peter Gates:ÌýComprehensive community initiatives: Million-dollar mistakes or the next best thing?

• Dr Emily Symes:ÌýSubstance use in trans and gender diverse adults: a global systematic review and meta-analysis

Session three

Ìý

NDARC has a proud history of partnering with clinicians, academics and industry stakeholders to translate its multidisciplinary research activities into best policy and practice. This session will highlight the evolution of smoking cessation guidelines in response to the unprecedented surge in vaping products, the results of the Tina Trial and its implications for stimulant treatment guidelines, and the extensive reviews on opioid dependence treatment and overdose prevention undertaken on behalf of the World Health Organization Guidelines Development Group. This will be followed by the NDARC Director's closing remarks.